Jump Financial LLC Buys Shares of 94,030 Janux Therapeutics, Inc. $JANX

Key Points

• Jump Financial LLC has acquired a new stake in Janux Therapeutics, Inc., buying 94,030 shares valued at approximately $2.54 million, representing 0.16% of the company.
• Several other major investors, including Price T Rowe Associates and Aberdeen Group plc, have significantly increased their positions in Janux, which now sees institutional ownership at 75.39%.
• Janux Therapeutics recently missed earnings expectations, reporting a loss of ($0.55) per share, with analysts forecasting a consensus target price of $86.90 and a "Buy" rating for the stock.

Jump Financial LLC acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 94,030 shares of the company's stock, valued at approximately $2,539,000. Jump Financial LLC owned approximately 0.16% of Janux Therapeutics at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its stake in Janux Therapeutics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 9,033 shares of the company's stock worth $244,000 after acquiring an additional 3,168 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Janux Therapeutics by 3.0% during the first quarter. New York State Common Retirement Fund now owns 16,435 shares of the company's stock worth $444,000 after acquiring an additional 471 shares in the last quarter. Millennium Management LLC bought a new stake in Janux Therapeutics during the fourth quarter worth about $6,216,000. California State Teachers Retirement System boosted its stake in Janux Therapeutics by 82.2% during the fourth quarter. California State Teachers Retirement System now owns 36,735 shares of the company's stock worth $1,967,000 after acquiring an additional 16,575 shares in the last quarter. Finally, KBC Group NV bought a new stake in Janux Therapeutics during the first quarter worth about $66,000. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Stock Down 1.4%

Janux Therapeutics stock traded down $0.33 during trading hours on Monday, hitting $22.72. The stock had a trading volume of 456,346 shares, compared to its average volume of 807,162. The stock has a market capitalization of $1.37 billion, a P/E ratio of -12.62 and a beta of 2.84. The stock's 50-day moving average price is $24.51 and its 200-day moving average price is $26.99. Janux Therapeutics, Inc. has a 12-month low of $21.97 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07). On average, research analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

JANX has been the topic of several research reports. Raymond James Financial initiated coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They set an "outperform" rating and a $65.00 price objective on the stock. Piper Sandler assumed coverage on shares of Janux Therapeutics in a report on Monday, August 18th. They issued an "overweight" rating and a $42.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, Janux Therapeutics has a consensus rating of "Buy" and an average target price of $86.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.